Investigating how these modifications influence the expression of crucial metabolic regulators, such as SREBPs and AMPK, could provide insights into the molecular underpinnings of MASLD in patients with a history of smoking. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.